Recruiting
An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread - CA030-001
Updated: 30 March, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy - Eastern Cooperative Oncology Group Performance Status of 0 or 1 - Some participants must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to solid tumor histologies - Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted for some patients - Understand and sign an IRB/IEC-approved ICF prior to any study-specific evaluation - Willing and able to comply with all study procedures Exclusion Criteria: - Participants with primary CNS malignancies, tumors with CNS metastases as the only site of disease, active brain metastases, or leptomeningeal metastasis will be excluded - Active, known, or suspected autoimmune disease - Participants with other active malignancy requiring concurrent intervention. - Prior organ allograft. Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
